<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149674_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152621</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>3</safetyreportversion>
		<safetyreportid>PHHY2011CA64715</safetyreportid>
		<primarysourcecountry>CA</primarysourcecountry>
		<occurcountry>CA</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20110714</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130117</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2011CA64715</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportertitle>Dr.</reportertitle>
			<reportergivename>Yves</reportergivename>
			<reporterfamilyname>Lappierre</reporterfamilyname>
			<reportercountry>CA</reportercountry>
			<qualification>1</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>CA</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>CA</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<primarysource>
			<reportergivename>Vanessa</reportergivename>
			<reporterfamilyname>Spyropoulos</reporterfamilyname>
			<reportercountry>CA</reportercountry>
			<qualification>3</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>JT</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19560725</patientbirthdate>
			<patientsex>1</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Knee arthroplasty</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20120426</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
				<patientmedicalcomment>Another knee surgery at the end og Aug 2012 as he had developed a knee infection post the first surg</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hip arthroplasty</patientepisodename>
				<patientmedicalcomment>Planning for surgery.</patientmedicalcomment>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Knee infection post surgery</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Joint infection</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Arthritis infective</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Left lower knee deep vein thrombosis following his surgery</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Deep vein thrombosis postoperative</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Deep vein thrombosis postoperative</reactionmeddrapt>
				<reactionoutcome>2</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Swelling at knee</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Swelling of knees</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Joint swelling</reactionmeddrapt>
				<reactionoutcome>2</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Low HB</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hemoglobin low</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Haemoglobin decreased</reactionmeddrapt>
				<reactionfirsttime>305</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Having diarrhea and had about 2-3 bowel movements/day</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Diarrhea</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Diarrhoea</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20110713</reactionstartdate>
				<reactionfirsttime>2</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>2</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>WBC low at 3.6</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>WBC decreased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>White blood cell count decreased</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120105</reactionstartdate>
				<reactionfirsttime>178</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>178</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120511</testdate>
				<testname>Haemoglobin</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>White blood cell count</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120105</testdate>
				<testname>White blood cell count</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>GILENYA</medicinalproduct>
				<obtaindrugcountry>CA</obtaindrugcountry>
				<drugauthorizationnumb>22-527</drugauthorizationnumb>
				<drugauthorizationcountry>CA</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>.5</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>0.5 mg, daily</drugdosagetext>
				<drugdosageform>Capsule</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Relapsing-remitting multiple sclerosis</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20110712</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20120312</drugenddate>
				<drugtreatmentduration>245</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>FINGOLIMOD</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Arthritis infective</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Arthritis infective</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Deep vein thrombosis postoperative</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Deep vein thrombosis postoperative</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Diarrhoea</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Diarrhoea</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Haemoglobin decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Haemoglobin decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Joint swelling</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Joint swelling</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>White blood cell count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>White blood cell count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>GILENYA</medicinalproduct>
				<obtaindrugcountry>CA</obtaindrugcountry>
				<drugauthorizationnumb>22-527</drugauthorizationnumb>
				<drugauthorizationcountry>CA</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>.5</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>0.5 mg, daily</drugdosagetext>
				<drugdosageform>Capsule</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>FINGOLIMOD</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Arthritis infective</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Arthritis infective</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Deep vein thrombosis postoperative</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Deep vein thrombosis postoperative</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Diarrhoea</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Diarrhoea</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Haemoglobin decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Haemoglobin decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Joint swelling</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Joint swelling</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>White blood cell count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>White blood cell count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2011CA64715, is an initial spontaneous report received from a consumer (patient) via Gilenya Go program on 14 Jul 2011 and follow up report from consumer (patient) received via Gilenya Go program on 05 Jan 2012 and follow up report received from nurse via Gilenya Go program on 07 Mar 2012 and combined follow up report received from consumer (patient) via Gilenya Go program on 07 May 2012 and from the physician on 11 May 2012 and follow-up report received from the physician on 20 Jun 2012 and combined follow up report received from the physician on 17 Jan 2013 and consumer (patient) via Gilenya Go program on 18 Jan 2013: This report refers to a 54-year-old male patient. This patient started treatment with Gilenya (fingolimod) at a daily dose of 0.5 mg for relapsing-remitting multiple sclerosis (RRMS) from 12 Jul 2011. On 13 Jul 2011, this patient started having diarrhea and had about 2-3 bowel movements per day. On 05 Jan 2012, this patient reported that he was informed by his orthopedic that his white blood cell count (WBC) decreased to 3.6 as per the recent blood test. Baseline WBC of the patient was 7.0. The patient stated that he was waiting for a hip replacement surgery on his left side. The date of surgery was unknown, but he was informed to stop Gilenya at least 4-6 weeks prior to surgery since his white blood cell count was low. He underwent a pre-planned knee replacement on 26 Apr 2012. He was diagnosed with left lower knee deep vein thrombosis (DVT) following his knee surgery. He was on Xarelto (rivaroxaban) 10 mg for 3 months or less. On 11 May 2012, his hemoglobin was reported as 90 (units unspecified). The physician planned to wait a little while before restarting the patient on Gilenya. The plan was to wait until the patient's hemoglobin and mobility had increased. It was reported that his neurologist would be notified about the events. It was reported that he had swelling at the knee and it was improving. The patient saw the orthopedic surgeon on 14 Jun 2012, who had tried to do a puncture to remove fluid from his knee, but he was unable to withdraw any liquid. Therefore, the swelling was thought to be related to inflammation. He was prescribed Apo-Naproxen twice daily (naproxen) and ferrous sulfate 300mg twice daily. The patient had to continue Xarelto (rivaroxaban) 15mg twice daily. He also wore compression stockings and had physiotherapy three times a week. The patient would be going for blood work next month. On an unspecified date in the end of Aug 2012, the patient underwent a second knee surgery as he had developed a knee infection post the surgery. He was treated with intravenous (IV) antibiotics for 6 weeks and with oral antibiotics for 5 weeks. The patient received last dose of Gilenya on 12 Mar 2012. Treatment with Gilenya was restarted on an unspecified date. The patient had his last follow up with the orthopedist on 03 Jan 2013. The physician reported the outcome of the events deep vein thrombosis postoperative and swelling of the knees as condition improving and not reported for other events. The physician assessed the event deep vein thrombosis postoperative as medically significant and not suspected to be related to Gilenya.

Consumer (patient) follow-up received via Gilenya-Go program on 05 Jan 2012: A new event with lab data was updated.

Follow-up report received from Gilenya-Go program nurse on 07 Mar 2012: Patient's hip and knee replacement surgery plan date was updated.

Combined follow up report received via Gilenya Go program from the consumer (patient) on 07 May 2012 and from the physician on 11 May 2012: Date of knee surgery, lab data, a new event (lower knee DVT) and its treatment was updated.

Follow-up report received from the physician on 20 Jun 2012: New event of knee swelling, its treatment and the outcome, date of knee replacement and last dose of Gilenya were updated.

Combined follow up report received from the physician on 17 Jan 2013 and  consumer (patient) via Gilenya Go program on 18 Jan 2013: Information related to procedure (second knee surgery in Aug 2012), new event (knee infection), treatment drug (antibiotics), action taken with Gilenya (restarted, reported by the physician) and medical narrative (last orthopedist follow-up on 03 Jan 2013) was updated.</narrativeincludeclinical>
				<sendercomment>Medic comment: The case is confounded by the history of surgical procedure. The event knee infection is conservatively assessed as suspected. The event DVT has been assessed as not-suspected in agreement with HCP reported causality and will be reassessed after the availability of follow up.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
